tbuckley/cabot-search huggingface dataset:
Treatment after TAVR — Discordance and Clinical Implications
Authors: Rick A. Nishimura, David R. Holmes
Journal: New England Journal of Medicine (2020)

Transcatheter aortic-valve replacement (TAVR) has transformed the treatment of severe aortic stenosis. However, questions remain regarding the long-term outcomes of this procedure, including the risk of thromboembolic complications and valve deterioration. It has been recognized that leaflet thrombosis of surgically implanted bioprosthetic valves may result in stenosis and could be reversed by oral anticoagulants.1 With TAVR, early leaflet thrombosis has been identified by hypoattenuated leaflet thickening and reduced leaflet motion on four-dimensional computed tomographic (CT) imaging in more than 15% of patients and could be a potentially treatable contributor to future adverse events.2,3 Although the long-term effects of hypoattenuated leaflet . . .
Single Institution Phase I Trial of the Novel Compound First-In-Class PDM08 in Refractory Solid Tumors (NCT01380249)
Authors: J. Barriuso, I. Soria, V. Moreno, M. Coronado, I. Galicia, M.A. Figueredo, J. Frias, J. Feliu, A. Carcas, J.L. Subiza
Journal: Annals of Oncology (2012)
Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: L.S. Schwartzberg, K. Tauer, J. Atkins, K. Sivarajan, V. Patel, B. Bastos, C. Langer, M.A. Socinski, D.R. Spigel
Journal: Annals of Oncology (2012)
Predicting Response Rates of High Grade Non Hodgkin's Lymphoma: A Comparative Study of International Prognostic Index (IPI) with Subjective Global Assessment (SGA)
Authors: V.S. Ostwal, P. Bagayatkar, P. Pawaskar, R. Thippeswamy, M. Sengar, H. Menon, N. Khattry, B. Bagal, R. Nair, M.K. Mallath
Journal: Annals of Oncology (2012)
Romiplostim in patients undergoing hematopoietic stem cell transplantation: results of a phase 1/2 multicenter trial
Authors: Régis Peffault de Latour, Sylvie Chevret, Anna Lisa Ruggeri, Felipe Suarez, Laetitia Souchet, David Michonneau, Flore Sicre de Fontbrune, Tereza Coman, Nathalie Dhedin, Marie Thérèse Rubio, Stéphanie Nguyen, Mohamad Mohty, Gérard Socié
Journal: Blood (2019)
Assessment and Comparison of Treatment Efficacy in Patients with Colorectal Cancer (CRC), Using a Novel Methodology to Estimate the Rate of Tumor Regression (D) and Growth (G)
Authors: M. Blanco Codesido, J. Wilkerson, L. Rodriguez Gayo, M. Rodriguez Alonso, P. Nava Garcia, A. Matas Ochoa, A.J. Muñoz Martín, S. Álvarez Suárez, P. García Alfonso, T. Fojo
Journal: Annals of Oncology (2012)
Clinical Profile and Patterns of Progression (PD) of Patients (PTS) with Advanced Non-Squamous Non-Small Cell Lung Cancer (NSNSCLC) Treated with First Line Bevacizumab (B): Avva Study
Authors: J. De Castro, J.M. Garcia-Bueno, M. Domine, S. Saura, R. Garcia-Gomez, M. Sereno, O. Juan, E. Pujol, B. Rubio, M. Cobo
Journal: Annals of Oncology (2012)
P-0292 Peri–Operative Outcomes of Abdominotransanal Resection With Total Mesorectal Excision and Transanal Handsewn Coloanal Anastomosis for Primary Distal Rectal Adenocarcinoma
Authors: Omar Ocampo, Marc Paul Lopez, Marie Dione Sacdalan, Hermogenes Monroy, Manuel Francisco Roxas
Journal: Annals of Oncology (2012)
Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer
Authors: J. Moss, A. Zick, A. Grinshpun, E. Carmon, M. Maoz, B.L. Ochana, O. Abraham, O. Arieli, L. Germansky, K. Meir, B. Glaser, R. Shemer, B. Uziely, Y. Dor
Journal: Annals of Oncology (2020)

Tumor-derived circulating cell-free DNA (cfDNA) is present in the plasma of individuals with cancer. Assays aimed at detecting common cancer mutations in cfDNA are being developed for the detection of several cancer types. In breast cancer, however, such assays have failed to detect the disease at a sensitivity relevant for clinical use, in part due to the absence of multiple common mutations that can be co-detected in plasma. Unlike individual mutations that exist only in a subset of tumors, unique DNA methylation patterns are universally present in cells of a common type and therefore may be ideal biomarkers. Here we describe the detection and quantification of breast-derived cfDNA using a breast-specific DNA methylation signature.We collected plasma from patients with localized breast cancer before and throughout treatment with neoadjuvant chemotherapy and surgery (N = 235 samples).Pretreatment breast cfDNA was detected in patients with localized disease with a sensitivity of 80% at 97% specificity. High breast cfDNA levels were associated with aggressive molecular tumor profiles and metabolic activity of the disease. During neoadjuvant chemotherapy, breast cfDNA levels decreased dramatically. Importantly, the presence of breast cfDNA towards the end of the chemotherapy regimen reflected the existence of residual disease.We propose that breast-specific cfDNA is a universal and powerful marker for the detection and monitoring of breast cancer.
Comparison of Comorbidity Treatment and Costs Associated With Bariatric Surgery Among Adults With Obesity in Canada
Authors: Jason A. Davis, Rhodri Saunders
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Information on the associations between barriers to delivery of bariatric surgery and poor weight trajectory afterward is lacking. Estimates are needed to inform decisions by administrators and clinicians to improve care. <h3>Objective</h3> To estimate the difference in patient-years of treatment for diabetes, hypertension, and dyslipidemia and public-payer cost between the Canadian standard and an improved bariatric surgery care pathway. <h3>Design, Setting, and Participants</h3> Economic evaluation of a decision analytic model comparing the outcomes of the standard care in Canada with an improved bariatric care pathway with earlier sleeve gastrectomy delivery and better postsurgical weight trajectory. The model was informed by published clinical data (101 studies) and meta-analyses (11 studies) between January and May 2019. Participants were a hypothetical 100-patient cohort with demographic characteristics derived from a Canadian study. <h3>Interventions</h3> Reduction of Canadian mean bariatric surgery wait time by 2.5 years following referral and improvement of patient postsurgery weight trajectory to levels observed in other countries. <h3>Main Outcomes and Measures</h3> Modeling weight trajectory after sleeve gastrectomy and resolution rates for comorbidities in Canada in comparison with an improved care pathway to estimate differences in patient-years of comorbidity treatment over 10 years following referral and the associated costs. <h3>Results</h3> For the 100-patient cohort (mean [SD] 88.2% [1.4%] female; mean [SD] age, 43.6 [9.2] years; mean [SD] body mass index, 49.4 [8.2]; and mean [SD] comorbidity prevalence of 50.0% [4.1%], 66.0% [3.9%], and 59.3% [4.0%] for diabetes, hypertension, and dyslipidemia, respectively) over 10 years following referral, the improved vs standard care pathway was associated with median reduction in patient-years of treatment of 324 (95% credibility interval [CrI], 249-396) for diabetes, 245 (95% CrI, 163-356) for hypertension, and 255 (95% CrI, 169-352) for dyslipidemia, corresponding to total savings of $900 000 (95% CrI, $630 000 to $1.2 million) for public payers in the base case. Relative to standard of care, the associated reduction in costs was approximately 29% (95% CrI, 20%-42%) in the improved pathway. Sensitivity analyses demonstrated independent associations of earlier surgical delivery and various levels of postsurgical weight trajectory improvements with overall savings. <h3>Conclusions and Relevance</h3> This study suggests that health care burden may be decreased through improvements to delivery and management of patients undergoing sleeve gastrectomy. More data are needed on long-term patient experience with bariatric surgery in Canada to inform better estimates.
T cell receptor and cytokine signal integration in CD8+ T cells is mediated by the protein Themis
Authors: Joanna Brzostek, Namrata Gautam, Xiang Zhao, Elijah W. Chen, Monika Mehta, Desmond W. H. Tung, Yen Leong Chua, Jiawei Yap, Su H. Cho, Shvetha Sankaran, Vasily Rybakin, Guo Fu, Nicholas R. J. Gascoigne
Journal: Nature Immunology (2020)
Statistical Examination to Determine whether only 48-H Value for Serum Concentration During High-Dose Methotrexate Therapy is a Predictor for Clinical Adverse Events using Ordered Logistic Regression Analysis
Authors: Y. Kanbayashi, K. Nomura, Y. Matsumoto, S. Horiike, M. Taniwaki
Journal: Annals of Oncology (2012)
Recognizing Emotional Expression as an Outcome Measure After Face Transplant
Authors: Miguel I. Dorante, Branislav Kollar, Doha Obed, Valentin Haug, Sebastian Fischer, Bohdan Pomahac
Journal: JAMA Network Open (2020)

Limited quantitative data exist on the restoration of nonverbal communication via facial emotional expression after face transplant. Objective and noninvasive methods for measuring outcomes and tracking rehabilitation after face transplant are lacking.To measure emotional expression as an indicator of functional outcomes and rehabilitation after face transplant via objective, noninvasive, and nonobtrusive software-based video analysis.This single-center case-control study analyzed videos with commercially available video analysis software capable of detecting emotional expression. The study participants were 6 patients who underwent face transplant at Brigham and Women's Hospital between April 2009 and March 2014. They were matched by age, race/ethnicity, culture, and sex to 6 healthy controls with no prior facial surgical procedures. Participants were asked to perform either emotional expressions (direct evaluation) or standardized facial movements (indirect evaluation). Videos were obtained in a clinical setting, except for direct evaluation videos of 3 patients that were recorded at the patients' residences. Data analysis was performed from June 2018 to November 2018.The possibility of detecting the emotional expressions of happiness, sadness, anger, fear, surprise, and disgust was evaluated using intensity score values between 0 and 1, representing expressions that are absent or fully present, respectively.Six patients underwent face transplant (4 men; mean [SD] age, 42 [14] years). Four underwent full face transplants, and 2 underwent partial face transplants of the middle and lower two-thirds of the face. In healthy controls, happiness was the only emotion reliably recognized in both indirect (mean [SD] intensity score, 0.92 [0.05]) and direct (mean [SD] intensity score, 0.91 [0.04]) evaluation. Indirect evaluation showed that expression of happiness significantly improved 1 year after transplant (0.04 point per year; 95% CI, 0.02 to 0.06 point per year; P = .002). Expression of happiness was restored to a mean of 43% (range, 14% to 75%) of that of healthy controls after face transplant. The expression of sadness showed a significant change only during the first year after transplant (-0.53 point per year; 95% CI, -0.82 to -0.24 point per year; P = .005). All other emotions were detectable with no significant change after transplant. Nearly all emotions were detectable in long-term direct evaluation of 3 patients, with expression of happiness restored to a mean of 26% (range, 5% to 59%) of that of healthy controls.Partial restoration of facial emotional expression is possible after face transplant. Video analysis software may provide useful clinical information and aid rehabilitation after face transplant.
Computational Staining of Pathology Images to Study the Tumor Microenvironment in Lung Cancer
Authors: Shidan Wang, Ruichen Rong, Donghan M. Yang, Junya Fujimoto, Shirley Yan, Ling Cai, Lin Yang, Danni Luo, Carmen Behrens, Edwin R. Parra, Bo Yao, Lin Xu, Tao Wang, Xiaowei Zhan, Ignacio I. Wistuba, John Minna, Yang Xie, Guanghua Xiao
Journal: Cancer Research (2020)

Abstract The spatial organization of different types of cells in tumor tissues reveals important information about the tumor microenvironment (TME). To facilitate the study of cellular spatial organization and interactions, we developed Histology-based Digital-Staining, a deep learning-based computation model, to segment the nuclei of tumor, stroma, lymphocyte, macrophage, karyorrhexis, and red blood cells from standard hematoxylin and eosin–stained pathology images in lung adenocarcinoma. Using this tool, we identified and classified cell nuclei and extracted 48 cell spatial organization-related features that characterize the TME. Using these features, we developed a prognostic model from the National Lung Screening Trial dataset, and independently validated the model in The Cancer Genome Atlas lung adenocarcinoma dataset, in which the predicted high-risk group showed significantly worse survival than the low-risk group (P = 0.001), with a HR of 2.23 (1.37–3.65) after adjusting for clinical variables. Furthermore, the image-derived TME features significantly correlated with the gene expression of biological pathways. For example, transcriptional activation of both the T-cell receptor and programmed cell death protein 1 pathways positively correlated with the density of detected lymphocytes in tumor tissues, while expression of the extracellular matrix organization pathway positively correlated with the density of stromal cells. In summary, we demonstrate that the spatial organization of different cell types is predictive of patient survival and associated with the gene expression of biological pathways. Significance: These findings present a deep learning-based analysis tool to study the TME in pathology images and demonstrate that the cell spatial organization is predictive of patient survival and is associated with gene expression. See related commentary by Rodriguez-Antolin, p. 1912
Maximum Standard Uptake Value at the Biopsy Site during 18F-Fluorodeoxyglucose Positron Emission Tomography does not Predict the Proliferation Potential of Tumor Cells in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Authors: Y. Ishii, N. Tomita, S. Sakata, K. Takeuchi, U. Tateishi, R. Watanabe, R. Sakai, Y. Ishigatsubo
Journal: Annals of Oncology (2012)
WNT-2, But not WNT-1 Expression Increases During Tumorgenesis in Breast, Prostate, Lung Cancer and Melanoma
Authors: A. Stanczak, A. Brozyna, H. Wisniewska, W. Jozwicki, L. Bodnar, M. Lamparska-Przybysz, M. Wieczorek
Journal: Annals of Oncology (2012)
Cancer Risks for PMS2-Associated Lynch Syndrome (vol 29, pg 2961, 2018)
Authors: Sanne W ten Broeke, Heleen M van der Klift, Carli Mj Tops, Stefan Aretz, Inge Bernstein, Daniel D Buchanan, Albert de la Chapelle, Gabriel Capella, Mark Clendenning, Christoph Engel, Steven Gallinger, Encarna Gomez Garcia, Jane C Figueiredo, Robert Haile, Heather L Hampel, Liselotte van Hest, John L Hopper, Nicoline Hoogerbrugge, Magnus von Knebel Doeberitz, Loic Le Marchand, Tom Gw Letteboer, Mark A Jenkins, Annika Lindblom, Noralane M Lindor, Arjen R Mensenkamp, Pal Moller, Polly A Newcomb, Theo Am van Os, Rachel Pearlman, Marta Pineda, Nils Rahner, Egbert Jw Redeker, Maran Jw Olderode-Berends, Christophe Rosty, Hans K Schackert, Rodney Scott, Leigha Senter, Liesbeth Spruijt, Verena Steinke-Lange, Manon Suerink, Stephen Thibodeau, Yvonne J Vos, Anja Wagner, Ingrid Winship, Frederik J Hes, Hans Fa Vasen, Juul T Wijnen, Maartje Nielsen, Aung Ko Win
Journal: Journal of Clinical Oncology (2019)

This corrects the article Cancer Risks for PMS2-Associated Lynch Syndrome in volume 36 on page 2961.
Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease
Authors: Yingyue Zhou, Wilbur M. Song, Prabhakar S. Andhey, Amanda Swain, Tyler Levy, Kelly R. Miller, Pietro L. Poliani, Manuela Cominelli, Shikha Grover, Susan Gilfillan, Marina Cella, Tyler K. Ulland, Konstantin Zaitsev, Akinori Miyashita, Takeshi Ikeuchi, Makoto Sainouchi, Akiyoshi Kakita, David A. Bennett, Julie A. Schneider, Michael R. Nichols, Sean A. Beausoleil, Jason D. Ulrich, David M. Holtzman, Maxim N. Artyomov, Marco Colonna
Journal: Nature Medicine (2020)
P-0222 Salvage Panitumumab in Kras Wild-Type Metastatic Colorectal Cancer Patients Without Progression on Prior Cetuximab-Based Regimens: A Multicenter, Matched-Pair, Case-Control Study
Authors: Filippo Pietrantonio, Pamela Biondani, Maria Di Bartolomeo, Federica Perrone, Vincenzo Ricci, Daris Ferrari, Federica Villa, Filippo Venturini, Gloria Barone, Elena Beretta, Luca Tondulli, Antonio Ghidini, Nadia Bianco, Sheila Piva, Filippo de Braud
Journal: Annals of Oncology (2012)
Efficacy and Safety of Somatuline Autogel in Combination with Molecular Targeted Therapies (MTT) in Neuroendocrine Tumors (NETS)
Authors: J. Capdevila, I. Sevilla, V. Alonso, L. Anton-Aparicio, P. Jimenez Fonseca, E. Grande, J.J. Reina, J.L. Manzano, J. Alonso-Jara, P. García Alfonso
Journal: Annals of Oncology (2012)
Genetic studies of urinary metabolites illuminate mechanisms of detoxification and excretion in humans
Authors: Pascal Schlosser, Yong Li, Peggy Sekula, Johannes Raffler, Franziska Grundner-Culemann, Maik Pietzner, Yurong Cheng, Matthias Wuttke, Inga Steinbrenner, Ulla T. Schultheiss, Fruzsina Kotsis, Tim Kacprowski, Lukas Forer, Birgit Hausknecht, Arif B. Ekici, Matthias Nauck, Uwe Völker, Gerd Walz, Peter J. Oefner, Florian Kronenberg, Robert P. Mohney, Michael Köttgen, Karsten Suhre, Kai-Uwe Eckardt, Gabi Kastenmüller, Anna Köttgen
Journal: Nature Genetics (2020)
Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1
Authors: Michael D. Crowther, Garry Dolton, Mateusz Legut, Marine E. Caillaud, Angharad Lloyd, Meriem Attaf, Sarah A. E. Galloway, Cristina Rius, Colin P. Farrell, Barbara Szomolay, Ann Ager, Alan L. Parker, Anna Fuller, Marco Donia, James McCluskey, Jamie Rossjohn, Inge Marie Svane, John D. Phillips, Andrew K. Sewell
Journal: Nature Immunology (2020)
Paramount: Descriptive Subgroup Analyses of Final Overall Survival (OS) for the Phase III Study of Maintenance Pemetrexed (PEM) Versus Placebo (PLB) Following Induction Treatment with PEM Plus Cisplatin (CIS) for Advanced Nonsquamous (NS) Non-Small Cell Lung Cancer (NSCLC)
Authors: M. Reck, L. Paz-Ares, F. De Marinis, O. Molinier, T. Prasad Sahoo, E. Laack, W. John, A. Zimmermann, C.M. Visseren-Grul, C. Gridelli
Journal: Annals of Oncology (2012)
Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study
Authors: D. Bianchini, Y. Loriot, E. Ileana, S. Sandhu, C. Pezaro, L. Albiges, G. Attard, K. Fizazi, J.S. de Bono, C. Massard
Journal: Annals of Oncology (2012)
S-1 And Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer
Authors: N. Takahara, H. Isayama, Y. Nakai, T. Sasaki, H. Ijichi, S. Mizuno, K. Miyabayashi, D. Mohri, K. Kawakubo, H. Kogure, N. Yamamoto, N. Sasahira, K. Hirano, M. Tada, K. Koike
Journal: Annals of Oncology (2012)
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
Authors: N. Omachi, T. Kawaguchi, A. Tamiya, T. Mimori, N. Takeuchi, Y. Matsuda, K. Asami, K. Okishio, S. Atagi, T. Okuma, A. Kubo, Y. Maruyama, S. Kudoh, M. Takada, K. Nishie
Journal: Annals of Oncology (2012)
Prediction of gestational diabetes based on nationwide electronic health records
Authors: Nitzan Shalom Artzi, Smadar Shilo, Eran Hadar, Hagai Rossman, Shiri Barbash-Hazan, Avi Ben-Haroush, Ran D. Balicer, Becca Feldman, Arnon Wiznitzer, Eran Segal
Journal: Nature Medicine (2020)
Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?
Authors: Louis Monnier, Anne Wojtusciszyn, Nicolas Molinari, Claude Colette, Eric Renard, David Owens
Journal: Diabetes Care (2020)

OBJECTIVE To evaluate the respective contributions of short-term glycemic variability and mean daily glucose (MDG) concentration to the risk of hypoglycemia in type 1 diabetes. RESEARCH DESIGN AND METHODS People with type 1 diabetes (n = 100) investigated at the University Hospital of Montpellier (France) underwent continuous glucose monitoring (CGM) on two consecutive days, providing a total of 200 24-h glycemic profiles. The following parameters were computed: MDG concentration, within-day glycemic variability (coefficient of variation for glucose [%CV]), and risk of hypoglycemia (presented as the percentage of time spent below three glycemic thresholds: 3.9, 3.45, and 3.0 mmol/L). RESULTS MDG was significantly higher, and %CV significantly lower (both P &amp;lt; 0.001), when comparing the 24-h glycemic profiles according to whether no time or a certain duration of time was spent below the thresholds. Univariate regression analyses showed that MDG and %CV were the two explanatory variables that entered the model with the outcome variable (time spent below the thresholds). The classification and regression tree procedure indicated that the predominant predictor for hypoglycemia was %CV when the threshold was 3.0 mmol/L. In people with mean glucose ≤7.8 mmol/L, the time spent below 3.0 mmol/L was shortest (P &amp;lt; 0.001) when %CV was below 34%. CONCLUSIONS In type 1 diabetes, short-term glycemic variability relative to mean glucose (i.e., %CV) explains more hypoglycemia than does mean glucose alone when the glucose threshold is 3.0 mmol/L. Minimizing the risk of hypoglycemia requires a %CV below 34%.
Efficacy and Safety of Chemoradiotherapy for Patients with Locoregional Lymph Node Recurrence of Esophageal Squamous Cell Carcinoma
Authors: T. Funakoshi, T. Tsushima, Y. Shibata, H. Tabuse, H. Sawai, S. Hamauchi, H. Taniguchi, A. Todaka, T. Yokota, N. Machida, K. Yamazaki, A. Fukutomi, H. Yasui, Y. Onozawa, N. Boku
Journal: Annals of Oncology (2012)
Optimal Cut-Points for QLQ-C30 Scales Associated With Overall Survival in Patients with Advanced Hepatocellular Carcinoma (AHCC): a Comparison of Two Methods
Authors: M. Diouf, F. Bonnetain, J. Barbare, O. Bouché, J. Meynier, L. Dahan, X. Paoletti, T. Filleron
Journal: Annals of Oncology (2012)
Study of the Safety and Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in 97 Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer
Authors: M. Ishibashi, K. Ogawa, S. Motizuki, S. Hanada, H. Uruga, H. Takaya, A. Miyamoto, N. Morokawa, T. Fujii, K. Kishi
Journal: Annals of Oncology (2012)
Correlation Between Circulating Tumor Cells (CTCS), PET/CT Response And Pathological Complete Response (PCR) in Primary HER2-Positive (HER2+) Breast Cancer Patients: A Sub-Study From the Neoaltto Trial
Authors: H.A. Azim, F. Rothe, C.M. Aura, M. Bavington, M. Maetens, G. Rouas, E. De Azambuja, C. Sotiriou, S. Di Cosimo, M. Ignatiadis
Journal: Annals of Oncology (2012)
Outcome of Oropharyngeal Cancer According to Treatment in Different Risk-Profile Groups: Analysis of a Retrospective Series of Patients Treated in a Tertiary Cancer Centre
Authors: P. Bossi, R. Granata, E. Orlandi, F. Perrone, L. Locati, C. Fallai, S. Pilotti, L. Ferraro, G. Scaramellini, L. Licitra
Journal: Annals of Oncology (2012)
Liposarcoma (LPS): Influence of Primary Tumor Site and Histological Sub-Type on Clinical Outcomes
Authors: S.L. Koo, A. Sairi, S. Pan, L. Foo Siang Sheng, T. Mann Hong, F. Chin, K. Sittampalam, M. Teo, M. Farid, R. Quek
Journal: Annals of Oncology (2012)